Connect with us
AstraZeneca’s Wainua missed its ATTR-CM endpoint, and the 1.14 combo ratio cements oral stabilizer pills as first-line care over gene silencers.
Rural patients lose Medicaid coverage and local hospital services under $1.1 trillion in tax-law health cuts a $50 billion rural fund does not offset.
474 Salmonella cases and two deaths are running through imported eggs in cafes, not Lion-marked shop eggs, and tracing that catering channel is taking weeks.
Prestige is pulling 39,060 Clear Eyes Maximum Itchy Eye Relief bottles, the same sterility-assurance gap that hit the brand in 2019.
NHS boards face ADHD and autism invoices from £300 to £3,000, while GPs can refuse shared care and local lists still hold hundreds of thousands.
Four XFG COVID-19 vaccines can ship after FDA approval, yet a frozen CDC panel leaves coverage and pharmacy access unsettled for high-risk patients.
Two Lancaster measles-associated deaths set off a fight with HHS, but kindergarten MMR coverage of 92.4 percent is the number that outlasts the argument.
England is offering HPV home testing kits to nearly 4 million under-screened women, copying a model Australia, the Netherlands and Sweden have already measured.
Roche and Lilly won FDA clearance for a pTau217 Alzheimer's blood test that sorts amyloid in primary care to feed antibody drugs.
The first myostatin blocker may win FDA clearance Sept. 30 for SMA, while obesity combos that revived the field still split on safety.
